🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU

Recruitingn/aAges 18 Years - 55 YearsFemaleShenzhen Maternity & Child Healthcare Hospital
NCT05500118 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

With the younger patients diagnosed with asymptomatic leiomyoma, delay in the reproductive age of women, the advancement of medical technology, and the rapid development of treatment methods, there are many choices between gynecologists, gynecologists and patients because of experience and knowledge. It is not easy to make the most favorable choice for patients. This study is mainly led by a committee composed of designers, doctors, nurses and patients, and based on clinical guidelines and evidence-based medicine. Co-operating with patients with asymptomatic small leiomyoma, we want to find the influencing factors of clinical decision-making, and to establish a patient decision aid tool. We use prospective trial to verify that the use of this tool can improve patients' decision-making efficacy and further improve patient-reported outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Diagnosis of leiomyoma: patients with leiomyoma diagnosed by imaging examinations (ultrasound and MRI) have no clinical symptoms; 2. Female with age in 18-55 years old; 3. The maximum diameter of a single leiomyoma is less than 5m, and the number does not exceed 10 by MRI; 4. No contraindications for sedation and analgesia; 5. Patients and their families agree to join this study, and can follow up on time. Exclusion Criteria: 1. History of myomectomy, including transabdominal, laparoscopic, hysteroscopy, etc.; 2. History of connective tissue diseases or radiotherapy, especially abdominal radiotherapy; 3. With pregnancy, acute inflammation of the reproductive tract, or other gynecological benign and malignant diseases such as endometriosis and ovarian tumors; 4. The maximum diameter of leiomyoma is greater than or equal to 5cm; 5. Suspected malignant tumor, such as sarcoma; 6. Those with language communication barriers and unable to cooperate with sedative and analgesic programs; 7. Abdominal scarring, when diagnosed by ultrasound transabdominal scan, has obvious sound attenuation (more than 10mm range).
💊

What it tests

  • Patients Decision Aids
📍

Where

1 site
Shenzhen Maternal and Child Health Hospital
Shenzhen, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy